NSE / BSEMaterials
β‚Ή407.25-3.80-0.92%
P/E18.9Mkt Capβ‚Ή3.60 K CrEV/EBITDA14.1

Aarti Drugs Limited

P/E18.9Mkt Capβ‚Ή3.60 K CrEV/EBITDA14.1
Company Profile

Aarti Drugs Limited, through its subsidiaries, manufactures and markets active pharmaceutical ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and formulations in India and internationally. The company offers aceclofenac, celecoxib, diclofenac sodium, diclodenac potassium, diclofenac diethylamine, diclofenac resinate, diclofenac epolamine, nimesulide, ciprofloxacin HCL, enrofloxacin base, gatifloxacin sesquihydrate, levofloxacin base, norfloxacin, ofloxacin, metronidazole, metronidazole benzoate, ornidazole, secnidazole, tinidazole, clopidogrel bisulphate, ticlopidine HCL, metformin HCL, pioglitazone HCL, teneligliptin, vildagliptin, fluconazole, ketoconazole, tolnaftate, zolpidem tartrate, niacin, raloxifene HCL, and acamprosate. It also provides benzene sulphonyl chloride, benzene sulphonic acid, methyl benzenesulfonate, sodium benzene sulfinate, para toluene sulphonyl chloride, methyl para toluenesulfonate, sodium para toluenesulfinate, para chlorobenzenesulfonyl chloride, formamide, calcium fluoride, potasium formate, benzenesulfonamide, ethyl p- toluenesulfonate, N,N',N'-tris-(4-toluene sulfonyl)-diethylenetriamine, ortho para toluene sulfonamides, ortho para toluene sulfonamides acid methyl ester, para chlorobenznesulfonamide, para toluenesulfonyl hydrazide, para toluenesulfonamide, and sodium benzenesulfonate. In addition, it offers pharma intermediate products, which includes Celecoxib, Ciprofloxacin, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Tinidazole, and Zolpidem. Further, the company develops drugs for antifungal, cardiovascular, and antidiabetic therapeutic areas, as well as non-steroidal anti-inflammatory drugs. The company was incorporated in 1984 and is headquartered in Mumbai, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–Ό 22.76% over 1Y
Monthly Returns

Historically, Apr has averaged the highest return (+13.7%); Mar the lowest (-8.5%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-7.6%Negative MonthJan 2026: -7.62%-3.5%Negative MonthFeb 2026: -3.54%-13.0%Negative MonthMar 2026: -12.97%+17.4%Positive MonthApr 2026: +17.42%+1.7%Neutral MonthMay 2026: +1.71%-0.9%Neutral MonthJun 2026: -0.93%+7.8%*Positive MonthJul 2026: +7.77%β€”β€”β€”β€”β€”
2025-11.9%Negative MonthJan 2025: -11.91%-13.4%Negative MonthFeb 2025: -13.42%-3.3%Negative MonthMar 2025: -3.29%+2.6%Positive MonthApr 2025: +2.63%+27.6%Positive MonthMay 2025: +27.58%+3.0%Positive MonthJun 2025: +3.02%+10.5%Positive MonthJul 2025: +10.50%-7.3%Negative MonthAug 2025: -7.31%+3.5%Positive MonthSep 2025: +3.49%+1.0%Neutral MonthOct 2025: +0.98%-13.3%Negative MonthNov 2025: -13.30%-3.2%Negative MonthDec 2025: -3.19%
2024+7.6%Positive MonthJan 2024: +7.61%-5.5%Negative MonthFeb 2024: -5.49%-12.8%Negative MonthMar 2024: -12.77%+16.3%Positive MonthApr 2024: +16.30%-5.8%Negative MonthMay 2024: -5.83%+6.1%Positive MonthJun 2024: +6.10%+1.4%Neutral MonthJul 2024: +1.37%+14.1%Positive MonthAug 2024: +14.10%-12.0%Negative MonthSep 2024: -12.01%-5.7%Negative MonthOct 2024: -5.74%-4.6%Negative MonthNov 2024: -4.57%-0.2%Neutral MonthDec 2024: -0.18%
2023-12.8%Negative MonthJan 2023: -12.85%-8.6%Negative MonthFeb 2023: -8.61%-7.8%Negative MonthMar 2023: -7.81%+24.6%Positive MonthApr 2023: +24.60%+3.8%Positive MonthMay 2023: +3.79%+6.4%Positive MonthJun 2023: +6.35%+28.0%Positive MonthJul 2023: +28.05%-3.8%Negative MonthAug 2023: -3.81%-4.9%Negative MonthSep 2023: -4.92%-13.7%Negative MonthOct 2023: -13.69%+3.5%Positive MonthNov 2023: +3.48%+0.6%Neutral MonthDec 2023: +0.64%
2022-7.5%Negative MonthJan 2022: -7.46%-9.5%Negative MonthFeb 2022: -9.53%-5.8%Negative MonthMar 2022: -5.84%+7.5%Positive MonthApr 2022: +7.48%-7.6%Negative MonthMay 2022: -7.60%-5.1%Negative MonthJun 2022: -5.14%+3.4%Positive MonthJul 2022: +3.38%+3.3%Positive MonthAug 2022: +3.31%+8.4%Positive MonthSep 2022: +8.43%+2.4%Positive MonthOct 2022: +2.42%-5.7%Negative MonthNov 2022: -5.67%+1.7%Neutral MonthDec 2022: +1.72%
2021β€”β€”β€”β€”β€”-2.3%Negative MonthJun 2021: -2.31%-5.6%Negative MonthJul 2021: -5.64%-7.8%Negative MonthAug 2021: -7.78%-1.3%Neutral MonthSep 2021: -1.32%-3.6%Negative MonthOct 2021: -3.61%-13.6%Negative MonthNov 2021: -13.56%+7.5%Positive MonthDec 2021: +7.51%
AvgΒ±SD-6.4%Β±7.4%-8.1%Β±3.4%-8.5%Β±3.8%+13.7%Β±7.8%+3.9%Β±12.6%+1.2%Β±4.3%+7.6%Β±10.5%-0.3%Β±8.2%-1.3%Β±7.0%-3.9%Β±5.7%-6.7%Β±6.3%+1.3%Β±3.5%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 0.989x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή2.17 K Crβ–Ό 4.1%
EBITDA Growthβ€”
Net Profitβ‚Ή157.00 Crβ–² 10.6%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–² 0.0%
Revenue CAGR 5Y6.8%
EBITDA CAGR 5Y1.2%
Net Profit CAGR 5Y0.9%
NP Growth 1Y10.6%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή2.17 K Crβ€”β‚Ή157.00 Crβ€”β€”12.5%-4.1%10.6%
Mar 2024β‚Ή2.27 K Crβ€”β‚Ή142.00 Crβ€”β€”12.1%-9.2%-7.2%
Mar 2023β‚Ή2.50 K Crβ€”β‚Ή153.00 Crβ€”β€”13.7%11.0%-21.5%
Mar 2022β‚Ή2.25 K Crβ€”β‚Ή195.00 Crβ€”β€”20.0%17.5%-24.4%
Mar 2021β‚Ή1.92 K Crβ€”β‚Ή258.00 Crβ€”β€”30.0%17.1%89.7%
Mar 2020β‚Ή1.64 K Crβ€”β‚Ή136.00 Crβ€”β€”21.9%12.4%56.3%
Mar 2019β‚Ή1.45 K Crβ€”β‚Ή87.00 Crβ€”β€”16.8%27.5%19.2%
Mar 2018β‚Ή1.14 K Crβ€”β‚Ή73.00 Crβ€”β€”16.8%4.7%-2.7%
Mar 2017β‚Ή1.09 K Crβ€”β‚Ή75.00 Crβ€”β€”19.4%1.2%13.6%
Mar 2016β‚Ή1.08 K Crβ€”β‚Ή66.00 Crβ€”β€”18.9%-1.0%-15.4%

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales9721,0871,0761,0891,1401,4541,6351,9152,2512,4982,2672,1742,237
Total Expenses8229159009109551,2521,3871,5111,9302,2121,9981,9081,949
EBIT / Operating Profit150172176179185203248404321286269265288
OPM %15%16%16%16%16%14%15%21%14%11%12%12%13%
Other Income110416975241414
Finance Costs37424738364136262336333228
Depreciation & Amortisation28313637384047484747484850
Profit Before Tax8610093108112128175338256205192199224
Tax %28%22%29%30%35%32%22%24%24%25%26%21%-
Net Profit / PAT627866757387136258195153142157190
EPS (β‚Ή)6.388.016.847.917.789.2514.5627.6521.0616.5015.4317.2420.87
Dividend Payout %26%41%25%3%3%3%3%9%5%6%6%6%-

Peer Comparison

Materials sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
Aarti Drugs Limitedthis co.β‚Ή3.60 K Crβ‚Ή2.17 K Cr18.902.6814.06-4.1%
UltraTech Cement Ltdβ‚Ή3.55 L Crβ‚Ή71.89 K Cr48.605.0227.234.7%
JSW Steel Limitedβ‚Ή2.88 L Crβ‚Ή1.28 L Cr38.003.4514.23-5.5%
Asian Paints Ltd.β‚Ή2.77 L Crβ‚Ή29.55 K Cr69.6014.5035.04-5.4%
Hindustan Zinc Ltd.β‚Ή2.66 L Crβ‚Ή33.97 K Cr25.5019.5718.5817.4%
Coal India Limitedβ‚Ή2.64 L Crβ‚Ή1.59 K Cr12.4013.2416.335.1%
Vedanta Limitedβ‚Ή2.49 L Crβ‚Ή74.30 K Cr26.503.3712.825.0%
Industry Averageβ€”β‚Ή10.75 K Cr47.545.2330.19121.8%

Learn while you research

Hand-picked academy chapters to deepen your understanding of Aarti Drugs Limited and the metrics that matter.

Browse the full Equiscale Academy